GL Pharm Tech Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Hun-Sik Wang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Güncelleme yok

Recent updates

Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?

Jul 23

Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% Higher

Mar 01

Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?

Mar 30

The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding On

Dec 15

CEO

Hun-Sik Wang (53 yo)

no data

Görev süresi

Mr. Wang serves as the Chief Executive Officer of GL PharmTech Corp.

GL Pharm Tech Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Recent updates

New major risk - Financial position

Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?

New minor risk - Share price stability

New minor risk - Shareholder dilution

Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)

W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund

GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd.

Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% Higher

Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)

New major risk - Financial position

New major risk - Share price stability

First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)

Third quarter 2022 earnings released: ₩5.00 loss per share (vs ₩5.00 loss in 3Q 2021)

Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?

The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding On

New 90-day high: ₩1,190

GL Pharm Tech Corp. announced that it expects to receive KRW 4.5 billion in funding from Ideal Priavate Equity 1 Co., Ltd.

New 90-day low: ₩875

GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd.

New 90-day low: ₩896

GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd.

CEO

Görev süresi